Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

VP, late development, immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson.

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in ...

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Eli Lilly is increasing Mounjaro's UK price by 170% to match European market levels, with the highest dose now costing £330.